Mr. Nick Kuzyk of Agra reports

AGRA VENTURES ANNOUNCES RECEIPT OF EARNOUT MILESTONE PAYMENT

Further to its news releases issued on April 6, 2021, and Sept. 8, 2021, Agra Ventures Ltd. received a portion of the final earnout milestone payment (FEMP) from Organigram Holdings Inc. on May 19, 2023. The final earnout milestone payment is related to the previously announced sale of Edibles & Infusions Corp. (EIC) to OGI by a group of stakeholders, including, but not limited to, the company.

Agra received approximately $1,034,000 of the FEMP, $5-million of which was paid to the vendors of EIC in the form of Organigram common shares. Specifically, Agra received 1,642,540 shares of Organigram through the Direct Registration System. The portion of earnout shares were issued at the price of 62.9476 cents, which is the five-day volume-weighted average price of Organigram's common shares on their date of issuance. The FEMP was triggered upon the EIC business successfully generating $15-million in net revenue during the 12 months ended Dec. 31, 2022.

Up to an additional $2-million in earnout shares may be subsequently received by Agra, subject to the outcome of outstanding contractual matters relating to the EIC divestiture. Information related to the receipt of a material level of additional earnout shares will be announced by the company by news release in due course.

Management commentary

"The achievement of the final earnout milestone and the receipt of the earnout shares is a testament to the high quality of the EIC asset and its associated business that was divested of by the vendor group. This portion of the final earnout milestone payment enhances Agra's current asset position and enables the company to continue on its current path," said Nick Kuzyk, chief executive officer and director of Agra Ventures.

About Agra Ventures Ltd.

Agra Ventures is a company with diversified assets focused on the cannabis industry. Agra Ventures' primary asset in Canada is its 70-per-cent ownership of Boundary Bay Cannabis, located in Delta, B.C. Boundary Bay Cannabis utilizes part of a large greenhouse complex in order to focus on the cost-optimized cultivation of high-potency cannabis. Abroad, the company's wholly owned subsidiary, Farmako GmbH, is focused on becoming Europe's leading distributor of medical cannabis as well as its proprietary CBD (cannabidiol) and THC (tetrahydrocannabinol) test kits. Farmako currently has active product distribution operations in Germany and is fully licensed in the United Kingdom.

We seek Safe Harbor.